“Diabetic Gastroparesis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Gastroparesis Market.
The Diabetic Gastroparesis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Gastroparesis Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Diabetic Gastroparesis treatment therapies with a considerable amount of success over the years.
-
Diabetic Gastroparesis companies working in the treatment market are CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others, are developing therapies for the Diabetic Gastroparesis treatment
-
Emerging Diabetic Gastroparesis therapies in the different phases of clinical trials are- CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others are expected to have a significant impact on the Diabetic Gastroparesis market in the coming years.
-
In September 2024, The US Food and Drug Administration (FDA) has rejected the new drug application (NDA) submitted by Vanda Pharmaceuticals for the use of tradipitant in treating gastroparesis symptoms.
Diabetic Gastroparesis Overview
Diabetic Gastroparesis is a condition that affects the stomach’s ability to empty its contents due to nerve damage caused by diabetes. The condition occurs when high blood sugar levels over time damage the vagus nerve, which controls the muscles of the stomach. This results in delayed gastric emptying, causing symptoms like nausea, vomiting, bloating, abdominal pain, and feeling full quickly after eating. It can lead to poor blood sugar control and malnutrition. Treatment focuses on managing blood sugar levels, dietary changes, and medications to improve stomach motility and relieve symptoms.
Get a Free Sample PDF Report to know more about Diabetic Gastroparesis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight
Emerging Diabetic Gastroparesis Drugs Under Different Phases of Clinical Development Include:
-
CIN-102: CinDome Pharma, Inc.
-
Metoclopramide Nasal Spray: Evoke Pharma
-
Tradipitant: Vanda Pharmaceuticals
-
IW-9179: Ironwood Pharmaceuticals
-
TAK-954: Takeda
-
NG101: Neurogastrx, Inc
-
CNSA-001: PTC Therapeutics
-
velusetrag: Theravance Biopharma
-
GM-611: Chugai Pharma
-
Camicinal: GlaxoSmithKline
-
PCS12852: Processa Pharmaceuticals
Diabetic Gastroparesis Route of Administration
Diabetic Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Diabetic Gastroparesis Molecule Type
Diabetic Gastroparesis Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Diabetic Gastroparesis Pipeline Therapeutics Assessment
-
Diabetic Gastroparesis Assessment by Product Type
-
Diabetic Gastroparesis By Stage and Product Type
-
Diabetic Gastroparesis Assessment by Route of Administration
-
Diabetic Gastroparesis By Stage and Route of Administration
-
Diabetic Gastroparesis Assessment by Molecule Type
-
Diabetic Gastroparesis by Stage and Molecule Type
DelveInsight’s Diabetic Gastroparesis Report covers around 8+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Diabetic Gastroparesis product details are provided in the report. Download the Diabetic Gastroparesis pipeline report to learn more about the emerging Diabetic Gastroparesis therapies
Some of the key companies in the Diabetic Gastroparesis Therapeutics Market include:
Key companies developing therapies for Diabetic Gastroparesis are – Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.
Diabetic Gastroparesis Pipeline Analysis:
The Diabetic Gastroparesis pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Gastroparesis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Gastroparesis Treatment.
-
Diabetic Gastroparesis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Diabetic Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Gastroparesis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Gastroparesis drugs and therapies
Diabetic Gastroparesis Pipeline Market Drivers
-
Growing prevalence of diabetes, Unmet medical need, Advancements in drug development, Improved awareness and diagnosis, Regulatory support for innovation, are some of the important factors that are fueling the Diabetic Gastroparesis Market.
Diabetic Gastroparesis Pipeline Market Barriers
-
However, Limited effective treatment options, Challenges in drug development, Adverse side effects, High treatment costs, Regulatory challenges, and other factors are creating obstacles in the Diabetic Gastroparesis Market growth.
Scope of Diabetic Gastroparesis Pipeline Drug Insight
-
Coverage: Global
-
Key Diabetic Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others
-
Key Diabetic Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others
-
Diabetic Gastroparesis Therapeutic Assessment: Diabetic Gastroparesis current marketed and Diabetic Gastroparesis emerging therapies
-
Diabetic Gastroparesis Market Dynamics: Diabetic Gastroparesis market drivers and Diabetic Gastroparesis market barriers
Request for Sample PDF Report for Diabetic Gastroparesis Pipeline Assessment and clinical trials
Table of Contents
1. Diabetic Gastroparesis Report Introduction
2. Diabetic Gastroparesis Executive Summary
3. Diabetic Gastroparesis Overview
4. Diabetic Gastroparesis- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Late Stage Products (Phase II/III)
7. Diabetic Gastroparesis Mid Stage Products (Phase II)
8. Diabetic Gastroparesis Early Stage Products (Phase I)
9. Diabetic Gastroparesis Preclinical Stage Products
10. Diabetic Gastroparesis Therapeutics Assessment
11. Diabetic Gastroparesis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Gastroparesis Key Companies
14. Diabetic Gastroparesis Key Products
15. Diabetic Gastroparesis Unmet Needs
16 . Diabetic Gastroparesis Market Drivers and Barriers
17. Diabetic Gastroparesis Future Perspectives and Conclusion
18. Diabetic Gastroparesis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/